0001171623-14-000001.txt : 20140904 0001171623-14-000001.hdr.sgml : 20140904 20140904132655 ACCESSION NUMBER: 0001171623-14-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140904 DATE AS OF CHANGE: 20140904 EFFECTIVENESS DATE: 20140904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DIFFUSION PHARMACEUTICALS LLC CENTRAL INDEX KEY: 0001171623 IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-224078 FILM NUMBER: 141082712 BUSINESS ADDRESS: STREET 1: 2020 AVON COURT, #4 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: 434-220-0718 MAIL ADDRESS: STREET 1: 2020 AVON COURT, #4 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 D 1 primary_doc.xml X0707 D LIVE 0001171623 DIFFUSION PHARMACEUTICALS LLC 2020 AVON COURT, #4 CHARLOTTESVILLE VA VIRGINIA 22902 434-220-0718 VIRGINIA None None Limited Liability Company true David G. Kalergis 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Executive Officer Director John L. Gainer 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Executive Officer Director Thomas E. Byrne 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Director Robert W. Adams 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Director Mark T. Giles 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Director Ben L. Shealy 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Executive Officer David R. Jones 2020 AVON COURT, #4 Charlottesville VA VIRGINIA 22902 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2014-06-30 false true true true true Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.50 per unit. false 0 3472000 3472000 0 false 30 0 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false DIFFUSION PHARMACEUTICALS LLC /s/ Ben L. Shealy Ben L. Shealy Chief Financial Officer 2014-08-29